Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 11 (November)

1. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
   Oncogene, 26(50): 7163-9. [Abstract] [Full-text]
2. Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification.
   Clin Cancer Res, 13(21): 6404-9. [Abstract] [Full-text]
3. The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor Positive Tumor Cells is Enhanced By Cytokines.
   Clin Cancer Res, 13(21): 6419-6428. [Abstract] [Full-text]
4. In Vitro Evaluation of Two Polyhedral Boron Anion Derivatives as Linkers for Attachment of Radioiodine to the Anti-HER2 Monoclonal Antibody Trastuzumab.
   Cancer Biother Radiopharm, 22(5): 585-96. [Abstract] [Full-text]
5. Adjuvant therapy of the very young woman.
   Breast, 16: 136-46. [Abstract] [Full-text]
6. Systemic adjuvant therapies and radiotherapy to the conserved breast: Strategies revisited.
   Breast, 16: 84-8. [Abstract] [Full-text]
7. Using clinical trial data to tailor adjuvant treatments for individual patients.
   Breast, 16: 98-104. [Abstract] [Full-text]
8. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
   Pharm Res, 24(12): 2402-11. [Abstract] [Full-text]
9. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
   Breast Cancer Res, 9(5): 111. [Abstract] [Full-text]
10. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment.
    Crit Rev Oncol Hematol, 64(3): 210-225. [Abstract] [Full-text]
11. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients.
    PLoS ONE, 2(11): e1138. [Abstract] [Full-text]
12. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients.
    Swiss Med Wkly, 137(39): 556-8. [Abstract] [Full-text]
13. Pancreatic cancer and the FAMMM syndrome.
    Fam Cancer. [Abstract] [Full-text]
14. Breast cancer brain metastases.
    Cancer Metastasis Rev, 26(3): 635-43. [Abstract] [Full-text]
15. A novel HPLC-UV-MS method for quantitative analysis of protein glycosylation.
    J Chromatogr B Analyt Technol Biomed Life Sci, 859(2): 178-91. [Abstract] [Full-text]
16. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
    J Neurooncol, 85(3): 311-7. [Abstract] [Full-text]
17. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
    Br J Cancer, 97(10): 1354-60. [Abstract] [Full-text]
18. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies.
    Clin Cancer Res, 13(22): 6639-48. [Abstract] [Full-text]
19. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
    Biomaterials, 29(4): 475-86. [Abstract] [Full-text]
20. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Mol Cancer Ther, 6(11): 2843-57. [Abstract] [Full-text]
21. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Bioconjug Chem, 18(6): 1956-64. [Abstract] [Full-text]
22. Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab?
    Pediatr Blood Cancer, 50(1): 163-6. [Abstract] [Full-text]
23. Will targeted therapy hold its promise? An evidence-based review.
    Curr Opin Oncol, 20(1): 104-11. [Abstract] [Full-text]
24. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
    Anticancer Drugs, 19(1): 1-7. [Abstract] [Full-text]
25. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    J Clin Oncol, 25(34): 5410-7. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.